Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among
Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among
Angelika Wientzek, Elisabeth Beyerlein, B. Ehlken, Ulf Stellmacher et al.
Journal
Pharmacoepidemiology and Drug Safety
Topics
Lung Cancer Treatments and Mutations
article
Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among
Angelika Wientzek, Elisabeth Beyerlein, B. Ehlken, Ulf Stellmacher, Annegret Gohlke